Sierra Oncology Inc (NASDAQ:SRRA) – Equities research analysts at Wedbush issued their Q1 2020 earnings estimates for shares of Sierra Oncology in a report issued on Monday, August 12th. Wedbush analyst R. Driscoll anticipates that the biotechnology company will post earnings per share of ($0.28) for the quarter. Wedbush also issued estimates for Sierra Oncology’s Q2 2020 earnings at ($0.19) EPS, Q3 2020 earnings at ($0.20) EPS and Q4 2020 earnings at ($0.20) EPS.

Sierra Oncology (NASDAQ:SRRA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20).

Other analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Thursday. ValuEngine upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

SRRA stock opened at $0.43 on Wednesday. The company’s 50 day simple moving average is $0.53 and its 200-day simple moving average is $1.20. The firm has a market capitalization of $35.23 million, a PE ratio of -0.57 and a beta of 1.24. Sierra Oncology has a 12 month low of $0.40 and a 12 month high of $2.07. The company has a debt-to-equity ratio of 0.06, a current ratio of 13.07 and a quick ratio of 13.07.

Several hedge funds have recently added to or reduced their stakes in SRRA. Renaissance Technologies LLC lifted its position in shares of Sierra Oncology by 22.0% during the 2nd quarter. Renaissance Technologies LLC now owns 2,312,634 shares of the biotechnology company’s stock worth $1,295,000 after purchasing an additional 417,300 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Sierra Oncology by 84.8% during the second quarter. Acadian Asset Management LLC now owns 899,221 shares of the biotechnology company’s stock valued at $504,000 after buying an additional 412,728 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Sierra Oncology by 981.2% during the second quarter. JPMorgan Chase & Co. now owns 43,703 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 39,661 shares during the period. Brookstone Capital Management purchased a new position in shares of Sierra Oncology during the first quarter valued at approximately $28,000. Finally, Virtu Financial LLC purchased a new position in shares of Sierra Oncology during the first quarter valued at approximately $32,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Sierra Oncology Company Profile

Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.

Further Reading: What does a hold rating mean?

Earnings History and Estimates for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.